Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects

Status Recruiting

Clinical Trial Summary

Drug metabolism in the liver is subject to large fluctuations (differences between women and men, people of different ethnic backgrounds, children and adults). These large differences are responsible for very different drug effects and side-effects (and especially liver damage caused by drugs) between individuals. Recent scientific findings suggest that blood derived cells can be used to model individual effects of drugs on the liver reflect inter-individual differences. Since liver damage caused by drugs is a diagnosis of exclusion, the aforementioned cells can be used to identify patients that show higher sensitivity to hepatotoxic side-effects and - in case several drugs are involved - identify the causal agent or possible interactions.

Clinical Trial Description

Drug-induced liver injury (DILI), especially its idiosyncratic for is often an unpredictable complication of drug therapy. Until now it is very challenging to predict occurrence, severity and outcome of DILI. Previous data provide evidence that cells from peripheral blood may reflect hepatocellular damage (Fannin RD, Hepatology. 2010). Own research could show that peripheral monocytes are capable to obtain several hepatocyte-like functions while maintaining individual characteristics of the donor, especially cytochrome P450 metabolism (Benesic, Gerbes, et al, Lab Invest 2012). This study investigates the effects of potentially hepatotoxic drugs on cells generated from patient blood in comparison to the clinical presentation. Its aim is the evaluation of in vitro tests using monocyte derived cells for diagnosis and exclusion of DILI and the potential to use the patient derived-cells for mechanistic investigations of DILI. 4 groups are investigated: 1) donors without liver disease 2) patients who will start a therapy with DILI-potential; 3) DILI patients; 4) patients with liver injuries other than DILI.

Patient history and clinical data are obtained and a single blood sample will be collected after informed consent. ;

Study Design

Related Conditions & MeSH terms

Adverse Reaction to Drug
Drug-induced Disorder of Liver
Drug-Related Side Effects and Adverse Reactions
Liver Diseases

Clinical Trial Details

NCT number	NCT02353455
Study type	Observational
Source	Ludwig-Maximilians - University of Munich
Contact	Andreas Benesic, MD
Phone	+49 89 44007
Email	andreas.benesic@med.uni-muenchen.de
Status	Recruiting
Phase
Start date	March 2013
Completion date	August 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01430702` - Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults	N/A
Active, not recruiting	`NCT01237275` - Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients	N/A
Terminated	`NCT02296840` - Post-operative Pain Control After Pediatric Adenotonsillectomy	Phase 4
Terminated	`NCT01600677` - Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions	N/A
Completed	`NCT02012712` - Personal Health Records and Elder Medication Use Quality	N/A
Completed	`NCT02609919` - Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age
Completed	`NCT06124417` - Efficacy and Safety of Sertraline in the Treatment of Maintenance Hemodialysis Patients With Depression	Phase 4
Recruiting	`NCT00817375` - Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients	N/A
Active, not recruiting	`NCT00935246` - Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning	N/A
Completed	`NCT04226443` - The Use of Midazolam and Remifentanil During Dialysis Access Procedures	N/A
Recruiting	`NCT02520570` - Post-market Safety Reassessment of Ulinastatin for Injection
Completed	`NCT01621373` - Exploratory Propofol Dose Finding Study In Neonates	Phase 2
Completed	`NCT02447679` - Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence	Phase 2
Recruiting	`NCT05645302` - Intensive Monitoring Scheme of Lidocaine Cataplasms
Enrolling by invitation	`NCT01830257` - Explore Active Surveillance Mode of the Community's Adverse Event Following Immunization(AEFI)	Phase 4
Recruiting	`NCT01354197` - The Thai Surgical Intensive Care Study (Thai-SICU Study)	N/A
Recruiting	`NCT04655794` - Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms